

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/792,214	03/04/2004	Sheng-Ping Zhong	12013/62704	4161	
23838 7590 02/14/2008 KENYON & KENYON LLP			EXAMINER		
1500 K STRE			PREBILIC, PAUL B		
SUITE 700 WASHINGTO	N. DC 20005		ART UNIT	PAPER NUMBER	
	. ,		3774		
			MAIL DATE	DELIVERY MODE	
			02/14/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)		
	10/792,214	ZHONG, SHENG-PING		
	Examiner	Art Unit		
	Paul B. Prebilic	3774		

The MAILING DATE of this communication appears on the cover sheet with the correspondence address
THE REPLY FILED 25 January 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
a) The period for reply expires 3 months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b) ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set fort in (a) above, if checked. Any reply received by the Office later than three months after the malling date of the final rejection, even if timely filled, may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).  AMENDMENTS
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) \( \sum \text{They raise new issues that would require further consideration and/or search (see NOTE below); (b) \( \sum \text{They raise the issue of new matter (see NOTE below);} \)
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) They present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7.  For purposes of appeal, the proposed amendment(s): a)  will not be entered, or b)  will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The above of the above (c): (a): (b): (b): (b): (c): (b): (c): (c): (c): (c): (c): (c): (c): (c
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>26.36.37 and 41-43</u> .
Claim(s) withdrawn from consideration:
AFFIDAVIT OR OTHER EVIDENCE
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant tis provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).
13. ⊠ Other: It was just noticed that claim 37 should state "said bio-active agent is" instead of "said bio-active agents are" to agree with base claim 26.
Paul B. Prebilic

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06) Primary Examiner Art Unit: 3774

## Continuation Sheet (PTOL-303)

## Application No.

Continuation of 3. NOTE: The proposed change to claim 26 appear to present a new Section 112 issue in that carbodiimide (claim 36) is bifunctional so it would conflict with the amended base claim. Claim 43 would have the same indefiniteness as mentioned in the Final Office action, and all the dependent claims would be of new combination that was considered previously for support or with resect to the prior art of record.